Small Study Offers Hope for Lung Cancer Patients

MAY 01, 2004
Susan Farley

In a study of patients with non?small-cell lung cancer, 3 of the 43 participants injected with the vaccine GVAX had no recurrence of lung cancer for more than 3 years. Researchers note that the trial was very small, and the vaccine is years away from reaching the market, if ever. The oncologist who led the study, John Nemunaitis, MD, of Baylor University Medical Center, said, "The results are very promising for patients with non?small-cell lung cancer, which is frequently resistant to chemotherapy." He added that this is the first study to show complete and long-lasting regression of lung cancer by stimulating the immune system to attack cancer cells. This type of lung cancer is the most common, killing more than 150,000 people each year.



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.